Perfusion System Market Size, Share & Trends Analysis Report By Application (Cardiopulmonary Perfusion System, Cell Perfusion System, Ex-vivo Organ Perfusion System), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global perfusion system market size was valued at USD 1.02 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 4.7% from 2022 to 2030. Factors such as an increase in the prevalence of cardiovascular and respiratory diseases, a rise in the number of organ transplants, growth in the geriatric population, and increasing cases of organ failures are expected to drive the growth of the market. Factors such as growing investment in cell-based research, government & NGO initiatives to encourage organ donations, and a rise in biologics manufacturing are also expected to boost the market growth in the coming years. The COVID-19 pandemic had a slightly negative impact on the market. While cardiac surgeries were still carried out due to their chronic and life-threatening nature, there was a significant drop in the number of organ donations and transplants due to government-imposed lockdowns and restrictions. Thus, the market experienced a significant fall in perfusion system sales during the pandemic.

Moreover, these lockdowns and restrictions disrupted the manufacturing processes as well as the overall supply chain across industries. They also resulted in disruption of research and development activities, which potentially led to the postponement of the launch of new products in the market. In addition, reduced patient visits to hospitals as a precautionary measure to avoid contracting the virus also had a significant negative impact on the industry.

However, with the world now returning to normalcy and countries majorly focusing on strengthening their healthcare setup, the market for perfusion systems is expected to continue generating a significant amount of revenue during the forecast period. With the imminent launch of new products, the market is expected to experience a pre-COVID growth rate during the forecast period.

A rise in the prevalence of cardiac and respiratory diseases is majorly contributing to the growth of the perfusion system market. Factors such as increasing consumption of processed food, a reduction in physical activity, and an increase in the overall lifespan of individuals, resulting in an increase in the geriatric population, are responsible for a rise in the prevalence of these disorders. According to the CDC’s 2022 data, in the U.S., every year about 805,000 people have a heart attack, and out of this, 605,000 people experience it for the first time.

A rise in the number of organ transplants is another factor that is expected to boost the market growth to a great extent during the forecast period. According to the preliminary data from the United Network of Organ Sharing, in 2021, the U.S. observed a 5.9% rise in organ transplants from 2020. The data also stated that, in 2021, around 13,861 Americans became deceased organ donors.  

Application Insights

The cardiopulmonary perfusion system held the highest revenue share of more than 43% in 2021, aided by the increasing prevalence of cardiovascular & respiratory diseases and a rapid rise in the number of organ transplant procedures being carried out across the globe. Based on application, the perfusion system market is segmented into cardiovascular perfusion system, cell perfusion system, and ex-vivo organ perfusion system.

The ex-vivo organ perfusion system accounted for almost 30% of the overall market share in 2021. This is because the ex-vivo perfusion system has the capability to allow organs to survive longer outside the body and make immediate transplants less urgent. This further helps the number of organs available for transplant to grow.

The cardiopulmonary perfusion system is further classified into oxygenators, heart-lung machines, perfusion pumps, cannula, monitoring systems, and others. The oxygenator segment held the largest revenue share in 2021 owing to the rising incidences of cardiopulmonary failure.

The cell perfusion system is further segmented into bioreactor perfusion system, microfluidic perfusion system, gravity/pressure-driven perfusion system, and small mammal organ perfusion system. The bioreactor perfusion system dominated the cell perfusion system segment with the highest share in 2021. This is attributed to factors such as the rising demand for biological products and the constant need to increase product yield & reduce production costs. 

The ex-vivo organ perfusion system is further segmented into hypothermic and normothermic. The hypothermic segment accounted for the highest market share of more than 63% in 2021. This can be attributed to the advantages that the hypothermic perfusion system offers, such as better long-term graft survival rates, the ability to provide metabolic support, and decreased vasospasm.

On the other hand, the normothermic perfusion systems held about 37% of the segment share in 2021. The subsegment is expected to experience steady growth during the forecast period, as it is not only beneficial in preserving extended criteria donor (ECD), but also offers the convenience of organ quality assessment.

Regional Insights

North America dominated the perfusion systems market with the highest revenue share of more than 39% in 2021. This is attributed to the enormous healthcare spending and advantageous health cover policies by both government and private insurers in the region. The growing number of organ donors is a major factor contributing to the growth of the regional perfusion systems demand. According to the Health Resources & Services Administration, in the U.S., more than 40,000 transplants were carried out in 2021.

However, the Asia Pacific region is projected to advance at the maximum CAGR of 5.5% during the forecast period. Factors such as an increase in the geriatric population, and the shift towards a sedentary lifestyle that is contributing to a rise in the prevalence of chronic diseases, are driving the growth of the market in this region. Various regional government initiatives are also anticipated to boost the growth of the perfusion systems market.

Moreover, in countries like India and China, the number of patients in need of an organ transplant is way higher than the number of organ donors, which is a cause of concern for the government and healthcare officials; therefore, these countries are focusing on developing various strategies to promote organ donation.

Key Companies & Market Share Insights

Key players manufacturing perfusion systems are focusing on various strategic initiatives to boost their market presence and overall position in the market. Launch of new products, strategic acquisitions & mergers, and partnerships are some of the initiatives carried out by these companies to strengthen their position in the market. For instance, in April 2022, LivaNova announced the commercial launch of the Essenz patient monitor. The monitor uses a patient-tailored approach to improve the efficiency and quality of care during cardiopulmonary bypass (CPB) procedures.

The following are some of the major players operating in the global perfusion system market:

• Getinge AB

• Medtronic, plc

• LivaNova

• Terumo Corporation

• Nipro Corporation

• XENIOS AG

• Repligen Corporation

• Spectrum Laboratories, Inc.

• Merck KGaA

• Harvard Bioscience, Inc.

• ALA Scientific Instruments, Inc.

• Lifeline Scientific, Inc.

• XVIVO Perfusion AB

Perfusion System Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For the purpose of this study, Grand View Research has segmented the global perfusion system market report on the basis of application and region:

• Application Outlook (Revenue, USD Million, 2017 - 2030)

  • Cardiopulmonary Perfusion System

    • Oxygenators

    • Heart-lung Machine

    • Perfusion Pumps

    • Cannula

    • Monitoring System

    • Others

  • Cell Perfusion System

    • Bioreactor Perfusion System

    • Microfluidic Perfusion System

    • Gravity/Pressure-driven Perfusion System

    • Small Mammal Organ Perfusion System

  • Ex-vivo Organ Perfusion System

    • Hypothermic

    • Normothermic

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE